A Prospective Randomized Controlled Trial of Preoperative Transarterial Chemoembolization for Resectable Large Hepatocellular Carcinoma
Phase 4
Completed
- Conditions
- Hepatocellular carcinomaCancer - Liver
- Registration Number
- ACTRN12608000577314
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Preoperative diagnosis of HCC > or =5 cm in diameter suitable for partial hepatectomy
Exclusion Criteria
Received other treatment before; history or presence of other malignancies; inadequate liver function
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival rate<br>(Disease-free survival was defined from the date of randomization to the time when recurrent tumor was first diagnosed.)[Every year after randomization for 5 years];Overall survival rate<br>(Overall survival was defined from the date of randomization to the time of death.)[Every year after randomization for 5 years];Recurrence rate<br>(The diagnosis of tumor recurrence was based on cytologic/histologic evidences or on the noninvasive diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL))[Every year after randomization for 5 years.]
- Secondary Outcome Measures
Name Time Method Resection rate<br>(Resectability was defined as tumor was resectable with potential clear surgical margins)[After surgery];Procedure-related complications, e.g. liver failure, bleeding, intra-abdominal collection[Discharge after surgery];Hospital mortality[Discharge after surgery]